Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Aditi Sapre"'
Autor:
Thomas Sudhop, Michael Reber, Diane Tribble, Aditi Sapre, William Taggart, Patrice Gibbons, Thomas Musliner, Klaus von Bergmann, Dieter Lütjohann
Publikováno v:
Journal of Lipid Research, Vol 50, Iss 10, Pp 2117-2123 (2009)
This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, pla
Externí odkaz:
https://doaj.org/article/245ccf5a96b741e9840048470f179342
Autor:
Heather, Platt, Tosin, Omole, Jose, Cardona, Neil J, Fraser, Richard A, Mularski, Charles, Andrews, Nizar, Daboul, Nancy, Gallagher, Aditi, Sapre, Jianing, Li, Adam, Polis, Doreen, Fernsler, Gretchen, Tamms, Weifeng, Xu, Rocio, Murphy, Julie, Skinner, Joseph, Joyce, Luwy, Musey
Publikováno v:
The Lancet Infectious Diseases. 23:233-246
A pneumococcal conjugate vaccine (PCV) specifically focused on serotypes associated with adult residual disease burden is urgently needed. We aimed to assess V116, an investigational 21-valent PCV, that contains pneumococcal polysaccharides (PnPs), w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7627609fe5446a34d4132311a5a452ab
https://doi.org/10.1016/s1473-3099(22)00526-6
https://doi.org/10.1016/s1473-3099(22)00526-6
Autor:
Heather Platt, Doreen Fernsler, Nancy Gallagher, Aditi Sapre, Adam Polis, Lori Hall, Gretchen Tamms, Howard Schwartz, Julie Skinner, Joseph Joyce, Rocio Murphy, Luwy Musey
Publikováno v:
JAC-Antimicrobial Resistance. 5
Background V116, an investigational 21-valent PCV, contains the following pneumococcal polysaccharides (PnPs): 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 16F, 17F, 19A, 20, 22F, 23A, 23B, 24F, 31, 33F, 35B, and a de-O-acetylated 15B (deOAc15B). This phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7fd1194f0a2ac2622699b4609d833c02
https://doi.org/10.1093/jacamr/dlac133.012
https://doi.org/10.1093/jacamr/dlac133.012
Autor:
Sukrut Shah, Ignacio Rodriguez Briones, Tanya B. Ashraf, Yale B. Mitchel, Yugang Dong, Wayne Huey-Heng Sheu, Sandra C. Tobias, Tayfun Sahin, Amy O. Johnson-Levonas, Yulia Moiseeva, P Rossi, Duk-Hyun Kang, Aditi Sapre, Christie M. Ballantyne, Ping Ye
Publikováno v:
The American journal of cardiology. 120(4)
This phase 3, multiregional, randomized, double-blind, placebo-controlled study assessed the efficacy/safety profile of anacetrapib added to ongoing therapy with statin ± other lipid-modifying therapies in patients with hypercholesterolemia who were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f88f7c89349f6b460508da7c4b7b87a
https://pubmed.ncbi.nlm.nih.gov/28624096
https://pubmed.ncbi.nlm.nih.gov/28624096
Autor:
Aditi Sapre, Klaus von Bergmann, Dieter Lütjohann, Patrice H. Gibbons, Thomas Musliner, William Taggart, Thomas Sudhop, Michael Reber, Diane Tribble
Publikováno v:
Journal of Lipid Research, Vol 50, Iss 10, Pp 2117-2123 (2009)
This study evaluates changes in cholesterol balance in hypercholesterolemic subjects following treatment with an inhibitor of cholesterol absorption or cholesterol synthesis or coadministration of both agents. This was a randomized, double blind, pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5228063e1004c80f47699d4ac91a015
https://doi.org/10.1194/jlr.p900004-jlr200
https://doi.org/10.1194/jlr.p900004-jlr200
Autor:
Debra Kush, Da Yi Hu, Christine McCrary Sisk, Waheeda Sirah, Hyo-Soo Kim, Ji Liu, John F. Paolini, Aditi Sapre, Darbie Maccubbin
Publikováno v:
Journal of Clinical Lipidology. 3:179-186
Niacin has proven lipid-modifying efficacy and cardiovascular benefit; however, it is underused because of skin flushing, a process mediated primarily by prostaglandin D(2) (PGD(2)). Laropiprant (LRPT), a PGD(2) receptor (DP1) antagonist that mitigat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f21e4e7eba9d5f23867e466b612fa6e
https://doi.org/10.1016/j.jacl.2009.04.048
https://doi.org/10.1016/j.jacl.2009.04.048
Autor:
Geraldine Macdonell, Dieter Lütjohann, Thomas Musliner, Waheeda Sirah, J. Lin, Amish P. Shah, Amy O. Johnson-Levonas, Aditi Sapre, K. von Bergmann
Publikováno v:
International Journal of Clinical Practice. 62:1499-1510
Summary Objective: To assess the long-term efficacy and safety profile of ezetimibe 10 mg/day in patients with homozygous sitosterolemia. Methods: This was an extension of a multi-centre, randomised, double-blind, placebo-controlled base study in whi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84db3dadbb5e96230b74cc385886169f
https://doi.org/10.1111/j.1742-1241.2008.01841.x
https://doi.org/10.1111/j.1742-1241.2008.01841.x
Autor:
Gerald Salen, Waheeda Sirah, C. McCrary Sisk, K. von Bergmann, Thomas Musliner, Dieter Lütjohann, Aditi Sapre, D. Cselovszky
Publikováno v:
International Journal of Clinical Practice. 62:995-1000
Summary Objective: To assess the effect of ezetimibe (EZE) 40 mg/day on non-cholesterol sterol plasma concentrations in patients with homozygous sitosterolaemia (HoS). Methods: This was a multi-centre, randomised, double-blind, placebo-controlled par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c24c6c2dfd9ad18f18cacd959bd4cbf
https://doi.org/10.1111/j.1742-1241.2008.01786.x
https://doi.org/10.1111/j.1742-1241.2008.01786.x
Publikováno v:
Clinical Therapeutics. 29:2419-2432
Background: Cholesterol-rich lipoproteins, including low-density lipoprotein cholesterol (LDL-C), intermediate-density lipoprotein cholesterol (IDL-C), and very-low-density lipoprotein cholesterol (VLDL-C), are known to promote atherosclerosis. Ezeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::09e3cb2d94676e41fd701506dc2c2398
https://doi.org/10.1016/j.clinthera.2007.10.004
https://doi.org/10.1016/j.clinthera.2007.10.004
Autor:
Jennifer Fable, Michiel Koeijvoets, G. Kees Hovingh, Yale B. Mitchel, Sukrut Shah, Amy O. Johnson-Levonas, Jean Bergeron, Naab Al-Saady, John J.P. Kastelein, Gisle Langslet, Aditi Sapre, Joost Besseling, John Hunter
Publikováno v:
Lancet, 385(9983), 2153-2161. Elsevier Limited
Present guidelines emphasise the importance of low concentrations of LDL cholesterol (LDL-C) in patients with familial hypercholesterolaemia. In most patients with the disease, however, these concentrations are not achieved with present treatments, s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5d106347dfa1330a984263e6f41a3ca
https://pure.amc.nl/en/publications/anacetrapib-as-lipidmodifying-therapy-in-patients-with-heterozygous-familial-hypercholesterolaemia-realize-a-randomised-doubleblind-placebocontrolled-phase-3-study(f0a930ee-34e5-4054-aba1-76b6963141e0).html
https://pure.amc.nl/en/publications/anacetrapib-as-lipidmodifying-therapy-in-patients-with-heterozygous-familial-hypercholesterolaemia-realize-a-randomised-doubleblind-placebocontrolled-phase-3-study(f0a930ee-34e5-4054-aba1-76b6963141e0).html
